ADAM Proteases and Gastrointestinal Function

Annual Review of Physiology

Volumn 78, Issue , 2016, Pages 243-276

  Jones, Jennifer C ^a   Rustagi, Shelly ^a   Dempsey, Peter J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ADAM10; ADAM17; EGFR; Intestinal stem cells; Notch; TNF

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MEMBRANE PROTEIN;

BIOSYNTHESIS; CARCINOGENESIS; CELL ADHESION; CELL COMMUNICATION; CELL FUNCTION; CELL LINEAGE; CELL SURFACE; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM CANCER; ENTERITIS; ENZYME SPECIFICITY; GASTROINTESTINAL TRACT FUNCTION; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINAL STEM CELL; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE INJURY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; ANIMAL; GASTROINTESTINAL TRACT; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADAM PROTEINS; ANIMALS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; SIGNAL TRANSDUCTION;

EID: 84958652284     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021014-071720     Document Type: Review

References (154)

1. Weber S, Saftig P. 2012. Ectodomain shedding and ADAMs in development. Development 139:3693-709
2. Edwards DR, Handsley MM, Pennington CJ. 2008. The ADAM metalloproteinases. Mol. Asp. Med. 29:258-89
3. Endres K, Fahrenholz F. 2012. Regulation of α-secretase ADAM10 expression and activity. Exp. Brain Res. 217:343-52
4. Reiss K, Saftig P. 2009. The "A disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 20:126-37
5. Scheller J, Chalaris A, Garbers C, Rose-John S. 2011. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32:380-87
6. Khokha R, Murthy A, Weiss A. 2013. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol. 13:649-65
7. Cho C. 2012. Testicular and epididymal ADAMs: expression and function during fertilization. Nat. Rev. Urol. 9:550-60
8. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. 2012. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 335:225-28
9. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, et al. 2012. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 335:229-32
10. Christova Y, Adrain C, Bambrough P, Ibrahim A, Freeman M. 2013. Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. EMBO Rep. 14:884-90
11. Maretzky T, McIlwain DR, Issuree PD, Li X, Malapeira J, et al. 2013. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. PNAS 110:11433-38
12. Li X, Maretzky T, Weskamp G, Monette S, Qing X, et al. 2015. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. PNAS 112:6080-85
13. Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, et al. 2012. TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals. J. Cell Biol. 199:481-96
14. Haining EJ, Yang J, Bailey RL, Khan K, Collier R, et al. 2012. The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J. Biol. Chem. 287:39753-65
15. Prox J, Willenbrock M, Weber S, Lehmann T, Schmidt-Arras D, et al. 2012. Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Cell Mol. Life Sci. 69:2919-32
16. Garbers C, Aparicio-Siegmund S, Rose-John S. 2015. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin Immunol. 34C:75-82
17. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, et al. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123:291-304
18. Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLOS Biol. 7:e1000215
19. Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, et al. 2006. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 393:609-18
20. Shimoda M, Principe S, Jackson HW, Luga V, Fang H, et al. 2014. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat. Cell Biol. 16:889-901
21. Folgosa L, Zellner HB, El Shikh ME, Conrad DH. 2013. Disturbed follicular architecture in B cell A disintegrin and metalloproteinase (ADAM)10 knockouts is mediated by compensatory increases in ADAM17 and TNF-αshedding. J. Immunol. 191:5951-58
22. Willems SH,TapeCJ, Stanley PL, Taylor NA,Mills IG, et al. 2010. Thiol isomerases negatively regulate the cellular shedding of ADAM17. Biochem. J. 428:439-50
23. Brew K, Nagase H. 2010. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 1803:55-71
24. Xu P, Derynck R. 2010. Direct activation of TACE-mediated ectodomain shedding by p38MAP kinase regulates EGF receptor-dependent cell proliferation. Mol. Cell 37:551-66
25. Xu P, Liu J, Sakaki-Yumoto M, Derynck R. 2012. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci. Signal 5:ra34
26. Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, et al. 2007. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J. Biol. Chem. 282:35712-21
27. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, et al. 2007. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. 13:1892-902
28. Zhou BB, Peyton M, He B, Liu C, Girard L, et al. 2006. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39-50
29. Murumkar PR, DasGupta S, Chandani SR, Giridhar R, Yadav MR. 2010. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin. Ther. Pat. 20:31-57
30. Tape CJ,Willems SH,Dombernowsky SL, Stanley PL, Fogarasi M, et al. 2011. Cross-domain inhibition of TACE ectodomain. PNAS 108:5578-83
31. Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, et al. 2012. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. J. Cell Sci. 125:6084-93
32. Tian H, Biehs B, Chiu C, Siebel CW,WuY, et al. 2015. Opposing activities ofNotch andWnt signaling regulate intestinal stem cells and gut homeostasis. Cell Rep. 11:33-42
33. Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, et al. 2013. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J. Clin. Investig. 123:1590-604
34. VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, et al. 2012. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development 139:488-97
35. Huntzicker EG, Hotzel K, Choy L, Che L, Ross J, et al. 2015. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology 61:942-52
36. Spence JR, Lauf R, Shroyer NF. 2011. Vertebrate intestinal endoderm development. Dev. Dyn. 240:501-20
37. Zorn AM, Wells JM. 2009. Vertebrate endoderm development and organ formation. Annu. Rev. Cell Dev. Biol. 25:221-51
38. Barker N. 2014. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 15:19-33
39. Clevers H. 2013. The intestinal crypt, a prototype stem cell compartment. Cell 154:274-84
40. Clevers HC, Bevins CL. 2013. Paneth cells: maestros of the small intestinal crypts. Annu. Rev. Physiol. 75:289-311
41. Sancho R, Cremona CA, Behrens A. 2015. Stem cell and progenitor fate in the mammalian intestine: Notch and lateral inhibition in homeostasis and disease. EMBO Rep. 16:571-81
42. Fre S,HuygheM,Mourikis P, Robine S, LouvardD, Artavanis-Tsakonas S. 2005. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435:964-68
43. Vooijs M, Ong CT, Hadland B, Huppert S, Liu Z, et al. 2007. Mapping the consequence of Notch1 proteolysis in vivo with NIP-CRE. Development 134:535-44
44. Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL, Murtaugh LC. 2011. Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing and adult pancreas. Development 138:431-41
45. Carulli AJ, Keeley TM, Demitrack ES, Chung J, Maillard I, Samuelson LC. 2015. Notch receptor regulation of intestinal stem cell homeostasis and crypt regeneration. Dev. Biol. 402:98-108
46. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, et al. 2008. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 9:377-83
47. Fre S, Pallavi SK, Huyghe M, Lae M, Janssen KP, et al. 2009. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. PNAS 106:6309-14
48. Pellegrinet L, Rodilla V, Liu Z, Chen S, Koch U, et al. 2011. Dll1-and Dll4-mediated Notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology 140:1230-40.e7
49. Kim TH, Li F, Ferreiro-Neira I, Ho LL, Luyten A, et al. 2014. Broadly permissive intestinal chromatin underlies lateral inhibition and cell plasticity. Nature 506:511-15
50. Tsai YH, VanDussen KL, Sawey ET, Wade AW, Kasper C, et al. 2014. ADAM10 regulates Notch function in intestinal stem cells of mice. Gastroenterology 147:822-34.e13
51. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, et al. 2002. The disintegrin/ metalloprotease ADAM 10 is essential forNotch signalling but not for α-secretase activity in fibroblasts. Hum. Mol. Genet. 11:2615-24
52. Groot AJ, Habets R, Yahyanejad S, Hodin CM, Reiss K, et al. 2014. Regulated proteolysis ofNOTCH2 and NOTCH3 receptors by ADAM10 and presenilins. Mol. Cell. Biol. 34:2822-32
53. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M. 2009. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J. Biol. Chem. 284:31018-27
54. Weber S, Niessen MT, Prox J, Lullmann-Rauch R, Schmitz A, et al. 2011. The disintegrin/ metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 138:495-505
55. Fre S, Hannezo E, Sale S, Huyghe M, Lafkas D, et al. 2011. Notch lineages and activity in intestinal stem cells determined by a new set of knock-in mice. PLOS ONE 6:e25785
56. Buczacki SJ, Zecchini HI, Nicholson AM, Russell R, Vermeulen L, et al. 2013. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495:65-69
57. Montgomery RK, Carlone DL, Richmond CA, Farilla L, KranendonkME, et al. 2011. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. PNAS 108:179-84
58. Tian H, Biehs B,Warming S, Leong KG, Rangell L, et al. 2011. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478:255-59
59. van Es JH, Sato T, van deWetering M, Lyubimova A, Nee AN, et al. 2012. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell Biol. 14:1099-104
60. Sangiorgi E, CapecchiMR. 2008. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 40:915-20
61. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, et al. 2005. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion,migration, and β-catenin translocation. PNAS 102:9182-87
62. Maretzky T, Scholz F, Koten B, Proksch E, Saftig P, Reiss K. 2008. ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis. J. Investig. Dermatol. 128:1737-46
63. Solanas G, Cortina C, Sevillano M, Batlle E. 2011. Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nat. Cell Biol. 13:1100-7
64. Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, et al. 2008. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin. Cancer Res. 14:1182-91
65. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385:733-36
66. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, et al. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943-52
67. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW,et al. 1998. An essential role for ectodomain shedding in mammalian development. Science 282:1281-84
68. Winsauer C, Kruglov AA, Chashchina AA, Drutskaya MS, Nedospasov SA. 2014. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev. 25:115-23
69. Sibilia M, Wagner EF. 1995. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-38
70. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, et al. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269:230-34
71. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, et al. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-41
72. Blobel CP, Carpenter G, Freeman M. 2009. The role of protease activity in ErbB biology. Exp. Cell Res. 315:671-82
73. Sunnarborg SW, Hinkle CL, StevensonM, Russell WE, Raska CS, et al. 2002. Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem. 277:12838-45
74. Strunk KE, Amann V, Threadgill DW. 2004. Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitioned. Genetics 167:1821-32
75. Gelling RW, Yan W, Al-Noori S, Pardini A, Morton GJ, et al. 2008. Deficiency of TNFαconverting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype inmice. Endocrinology 149:6053-64
76. Li N, Boyd K, Dempsey PJ, Vignali DA. 2007. Non-cell autonomous expression of TNF-α-converting enzyme ADAM17 is required for normal lymphocyte development. J. Immunol. 178:4214-21
77. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, et al. 2011. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365:1502-8
78. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, et al. 2012. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J. Exp. Med. 209:1105-19
79. Brandl K, Sun L, Neppl C, Siggs OM, Le Gall SM, et al. 2010. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. PNAS 107:19967-72
80. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, et al. 2010. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J. Exp. Med. 207:1617-24
81. Yan F, Liu L, Dempsey PJ, Tsai YH, Raines EW, et al. 2013. A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. J. Biol. Chem. 288:30742-51
82. Feng Y, Tsai YH,Xiao W, RallsMW,Stoeck A, et al. 2015. Loss of ADAM17-mediatedTNFαsignaling in intestinal cells attenuates mucosal atrophy in a mouse model of parenteral nutrition. Mol. Cell. Biol. 35:3604-21
83. Lee D, Yu M, Lee E, Kim H, Yang Y, et al. 2009. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J. Clin. Investig. 119:2702-13
84. Rowland KJ, McMellen ME, Wakeman D, Wandu WS, Erwin CR, Warner BW. 2012. Enterocyte expression of epidermal growth factor receptor is not required for intestinal adaptation in response to massive small bowel resection. J. Pediatr. Surg. 47:1748-53
85. Yan F, Cao H, Cover TL, Washington MK, Shi Y, et al. 2011. Colon-specific delivery of a probioticderived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Investig. 121:2242-53
86. Zhang Y, Dube PE,WashingtonMK, Yan F, Polk DB. 2012. ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival. Lab. Investig. 92:437-50
87. Frey MR, Polk DB. 2014. ErbB receptors and their growth factor ligands in pediatric intestinal inflammation. Pediatr. Res. 75:127-32
88. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, et al. 2012. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149:146-58
89. Wong VW, Stange DE, Page ME, Buczacki S,Wabik A, et al. 2012. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat. Cell Biol. 14:401-8
90. Horiuchi K, KimuraT,MiyamotoT,Takaishi H, OkadaY, et al. 2007. Cutting edge:TNF-α-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179:2686-89
91. Saha A, Backert S,Hammond CE,Gooz M, Smolka AJ. 2010. Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase αsubunit. Gastroenterology 139:239-48
92. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, et al. 2011. A Staphylococcus aureus poreforming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat. Med. 17:1310-14
93. Wilke GA, Wardenburg JB. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus α-hemolysin-mediated cellular injury. PNAS 107:13473-78
94. Sears CL, Geis AL, Housseau F. 2014. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J. Clin. Investig. 124:4166-72
95. Bonazzi M, Lecuit M, Cossart P. 2009. Listeria monocytogenes internalin and E-cadherin: from bench to bedside. Cold Spring Harb. Perspect. Biol. 1:a003087
96. Naglich JG, Metherall JE, RussellDW,Eidels L. 1992. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69:1051-61
97. Dube P, Punit S, PolkDB. 2014. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 308:G161-70
98. Leppkes M, Roulis M, Neurath MF, Kollias G, Becker C. 2014. Pleiotropic functions of TNF-αin the regulation of the intestinal epithelial response to inflammation. Int. Immunol. 26:509-15
99. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, et al. 2002. Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 51:37-43
100. Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, et al. 2009. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 296:G1332-43
101. Colon AL, Menchen LA, Hurtado O, De Cristobal J, Lizasoain I, et al. 2001. Implication of TNF-α convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 16:220-26
102. Forsyth CB, Banan A, Farhadi A, Fields JZ, Tang Y, et al. 2007. Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J. Pharmacol. Exp. Ther. 321:84-97
103. KirkegaardT, PedersenG, SaermarkT, Brynskov J. 2004. Tumour necrosis factor-αconverting enzyme (TACE) activity in human colonic epithelial cells. Clin. Exp. Immunol. 135:146-53
104. Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, et al. 2013. High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 19:501-11
105. Egger B, Procaccino F, Lakshmanan J, ReinshagenM,Hoffmann P, et al. 1997. Mice lacking transforming growth factor α have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 113:825-32
106. Egger B, Schmid SW, Naef M, Wildi S, Buchler MW. 2000. Efficacy and safety of weight-adapted nadroparin calcium versus heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. Dig. Surg. 17:602-9
107. Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB. 2009. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 136:217-26
108. Sahin U,Weskamp G, Kelly K, Zhou HM, Higashiyama S, et al. 2004. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164:769-79
109. Lu N, Wang L, Cao H, Liu L, Van Kaer L, et al. 2014. Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J. Immunol. 192:1013-23
110. NeufertC, BeckerC,TureciO,WaldnerMJ, Backert I, et al. 2013. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J. Clin. Investig. 123:1428-43
111. Hilliard VC, Frey MR, Dempsey PJ, Peek RM Jr, Polk DB. 2011. TNF-αconverting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival. Am. J. Physiol. Gastrointest. Liver Physiol. 301:G338-46
112. RioC,Buxbaum JD, Peschon JJ, Corfas G. 2000.Tumornecrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J. Biol. Chem. 275:10379-87
113. VecchiM, Rudolph-Owen LA, Brown CL, Dempsey PJ, Carpenter G. 1998. Tyrosine phosphorylation and proteolysis: pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J. Biol. Chem. 273:20589-95
114. Tsai Y-H, Feng Y, Wade AW, Teitelbaum DH, Dempsey PJ. 2012. Intestinal cell responses in different injury/regeneration models are differentially dependent on ADAM17. Gastroenterology 142:S61
115. Demehri FR, Barrett M, Ralls MW, Miyasaka EA, Feng Y, Teitelbaum DH. 2013. Intestinal epithelial cell apoptosis and loss of barrier function in the setting of altered microbiota with enteral nutrient deprivation. Front. Cell Infect. Microbiol. 3:105
116. Feng Y, Teitelbaum DH. 2012. Epidermal growth factor/TNF-α transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral nutrition. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G236-49
117. Feng Y, Tsai YH, Teitelbaum DH, Dempsey PJ. 2012. Intestinal epithelial cell responses to total parenteral nutrition (TPN) are under complex regulation by ADAM17. Gastroenterology 142:S167-68
118. Feng Y, Teitelbaum DH. 2013. Tumour necrosis factor-α-induced loss of intestinal barrier function requires TNFR1 and TNFR2 signalling in a mouse model of total parenteral nutrition. J. Physiol. 591:3709-23
119. Roulis M, Armaka M, Manoloukos M, Apostolaki M, Kollias G. 2011. Intestinal epithelial cells as producers but not targets of chronicTNFsuffice to cause murine Crohn-like pathology.PNAS108:5396-401
120. Stadnyk AW. 2002. Intestinal epithelial cells as a source of inflammatory cytokines and chemokines. Can. J. Gastroenterol. 16:241-46
121. Xue X, Ramakrishnan S, Anderson E,TaylorM, Zimmermann EM, et al. 2013. Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 145:831-41
122. McMahan RS, Riehle KJ, FaustoN, Campbell JS. 2013. A disintegrin andmetalloproteinase 17 regulates TNF and TNFR1 levels in inflammation and liver regeneration in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 305:G25-34
123. Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, et al. 2005. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J. Biol. Chem. 280:1826-37
124. CoantN, Ben Mkaddem S, Pedruzzi E, Guichard C,Treton X, et al. 2010.NADPHoxidase 1 modulates WNT and NOTCH1 signaling to control the fate of proliferative progenitor cells in the colon. Mol. Cell. Biol. 30:2636-50
125. Zheng X, Tsuchiya K,Okamoto R, IwasakiM, Kano Y, et al. 2011. Suppression of hath1 gene expression directly regulated by hes1 viaNotch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm. Bowel. Dis. 17:2251-60
126. GersemannM, Stange EF, Wehkamp J. 2011. From intestinal stem cells to inflammatory bowel diseases. World J. Gastroenterol. 17:3198-203
127. Radtke F, MacDonald HR, Tacchini-Cottier F. 2013. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 13:427-37
128. Xu H, Zhu J, Smith S, Foldi J, Zhao B, et al. 2012. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13:642-50
129. Tsai YH, Rakshit R, Chung J, Maillard I, Dempsey PJ. 2013. Myeloid-specific deletion of ADAM10 dramatically increases susceptibility to DSS-induced colitis. Gastroenterology 144:S308
130. DuffyMJ, McKiernan E, O'DonovanN,McGowan PM. 2009. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 15:1140-44
131. Murphy G. 2008. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8:929-41
132. Noah TK, Shroyer NF. 2013. Notch in the intestine: regulation of homeostasis and pathogenesis. Annu. Rev. Physiol. 75:263-88
133. van Es JH, van GijnME, Riccio O, van den Born M, Vooijs M, et al. 2005. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959-63
134. Peignon G, Durand A, Cacheux W, Ayrault O, Terris B, et al. 2011. Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut 60:166-76
135. Tsai YH, Feng Y, Rakshit R, Fearon ER, Dempsey PJ. 2013. Cell-autonomous ADAM10 signaling is required for adenoma initiation after APC mutation. Gastroenterology 144:S51-52
136. Chanrion M, Kuperstein I, BarriereC, ElMarjou F,Cohen D, et al. 2014. ConcomitantNotch activation and p53 deletion trigger epithelial-to-mesenchymal transition andmetastasis inmouse gut. Nat.Commun. 5:5005
137. Sonoshita M, Itatani Y, Kakizaki F, Sakimura K, Terashima T, et al. 2015. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov. 5:198-211
138. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, et al. 2013. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23:171-85
139. FiskeWH, Threadgill D, Coffey RJ. 2009. ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp. Cell Res. 315:583-601
140. Dong J, Opresko LK, Dempsey PJ, Lauffenburger DA, Coffey RJ, Wiley HS. 1999. Metalloproteasemediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. PNAS 96:6235-40
141. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, et al. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 22:304-17
142. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, et al. 2014. ADAM17-dependent c-MET-STAT3 signalingmediates resistance toMEKinhibitors in KRAS mutant colorectal cancer. Cell Rep. 7:1940-55
143. Waldner MJ, Neurath MF. 2014. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin. Immunol. 26:75-79
144. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6:583-88
145. Becker C, FantiniMC, SchrammC,LehrHA, Wirtz S, et al. 2004. TGF-βsuppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491-501
146. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, et al. 2010. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 184:1543-51
147. MitsuyamaK,Matsumoto S, Rose-John S, SuzukiA,HaraT, et al. 2006.STAT3activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55:1263-69
148. SchlomannU,KollerG,ConradC, Ferdous T, Golfi P, et al. 2015.ADAM8as a drug target in pancreatic cancer. Nat. Commun. 6:6175
149. Sato T, CleversH. 2013. Growing self-organizingmini-guts from a single intestinal stem cell: mechanism and applications. Science 340:1190-94
150. Weber S,Wetzel S, Prox J, Lehmann T, Schneppenheim J, et al. 2013. Regulation of adult hematopoiesis by the a disintegrin and metalloproteinase 10 (ADAM10). Biochem. Biophys. Res. Commun. 442:234-41
151. Yoda M, Kimura T, Tohmonda T, Uchikawa S, Koba T, et al. 2011. Dual functions of cell-autonomous and non-cell-autonomous ADAM10 activity in granulopoiesis. Blood 118:6939-42
152. Faber TW, Pullen NA, Fernando JF, Kolawole EM, McLeod JJ, et al. 2014. ADAM10 is required for SCF-induced mast cell migration. Cell. Immunol. 290:80-88
153. Gibb DR, El Shikh M, Kang DJ, Rowe WJ, El Sayed R, et al. 2010. ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. J. Exp. Med. 207:623-35
154. Chaimowitz NS, Martin RK, Cichy J, Gibb DR, Patil P, et al. 2011. A disintegrin and metalloproteinase 10 regulates antibody production and maintenance of lymphoid architecture. J. Immunol. 187:5114-22